{"transactions":[{"id":736217,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T22:19:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":8188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":8188,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":8188},"source":{"system":"sec-edgar","filing":"0001786966-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000003/primarydocument.xml","form_type":"4"}},{"id":736216,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-16T22:19:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":5619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":5619,"derivative":{"exercise_price":0,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":5619},"source":{"system":"sec-edgar","filing":"0001786966-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000003/primarydocument.xml","form_type":"4"}},{"id":932333,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":13690,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2021-03-04","expiration_date":"2028-04-26","underlying":"Common Stock","underlying_shares":13690},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932332,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":17236,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2023-10-16","expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":17236},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932331,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":7605,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.71,"exercise_date":"2024-09-02","expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":7605},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932330,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":66477,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2024-02-03","expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":66477},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932329,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":10463,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2024-12-03","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":10463},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932328,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":66477,"price":29.44,"value":1957082.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19820,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932327,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":10463,"price":29.44,"value":308030.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":86297,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932326,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":7605,"price":29.44,"value":223891.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":96760,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932325,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":17236,"price":29.44,"value":507427.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104365,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932324,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":13690,"price":29.44,"value":403033.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":121601,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932323,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":7605,"price":0.71,"value":5399.55,"ownership":{"direct":true},"balance_after":135291,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932322,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":66477,"price":1.93,"value":128300.61,"ownership":{"direct":true},"balance_after":127686,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932321,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":10463,"price":1.93,"value":20193.59,"ownership":{"direct":true},"balance_after":61209,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932320,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":17236,"price":0.64,"value":11031.04,"ownership":{"direct":true},"balance_after":50746,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932319,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":13690,"price":0.39,"value":5339.1,"ownership":{"direct":true},"balance_after":33510,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":1094093,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78960,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":43,"underlying":"Common Stock","underlying_shares":78960},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094092,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":38.4,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094091,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":27.64,"underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094090,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":33.66,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094089,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":149470,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":2.3,"underlying":"Common Stock","underlying_shares":149470},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094088,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3868,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":1.65,"underlying":"Common Stock","underlying_shares":3868},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094087,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Performance Share Units","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33778,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents restricted share units subject to performance-based vesting conditions (each, a \"PSU\") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33778},"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1094086,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-02T16:26:13.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":169712,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 66,931 shares underlying restricted stock units (each, an \"RSU\") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a \"Parent Cash-Based RSU Award\"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065322","document":"tm2519678-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925065322/tm2519678-15_4seq1.xml","form_type":"4"}},{"id":1106350,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T23:37:16.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":14.68,"exercise_date":"2026-06-16","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-25-004960","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218025004960/primarydocument.xml","form_type":"4"}},{"id":1221409,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T18:33:49.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":56.2025,"value":22481.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.90 to $56.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":169712,"source":{"system":"sec-edgar","filing":"0001104659-25-021008","document":"tm258294-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925021008/tm258294-2_4seq1.xml","form_type":"4"}},{"id":1221408,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T18:33:49.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":3598,"price":55.1225,"value":198330.755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.74 to $55.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":170112,"source":{"system":"sec-edgar","filing":"0001104659-25-021008","document":"tm258294-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925021008/tm258294-2_4seq1.xml","form_type":"4"}},{"id":1221407,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T18:33:49.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":12078,"price":54.2582,"value":655330.5396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.73 to $54.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":173710,"source":{"system":"sec-edgar","filing":"0001104659-25-021008","document":"tm258294-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925021008/tm258294-2_4seq1.xml","form_type":"4"}},{"id":1221406,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T18:33:49.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":3924,"price":53.1218,"value":208449.9432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.725 to $53.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":185788,"source":{"system":"sec-edgar","filing":"0001104659-25-021008","document":"tm258294-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925021008/tm258294-2_4seq1.xml","form_type":"4"}},{"id":1271031,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-12T19:55:53.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":53.1265,"value":1593795.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":189712,"source":{"system":"sec-edgar","filing":"0001104659-25-012359","document":"tm256428-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925012359/tm256428-1_4seq1.xml","form_type":"4"}},{"id":1303126,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T16:32:37.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":78960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in forty-eight (48) equal monthly installments following January 10, 2025, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":78960,"derivative":{"exercise_price":43,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":78960},"source":{"system":"sec-edgar","filing":"0001104659-25-003462","document":"tm253183-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925003462/tm253183-3_4seq1.xml","form_type":"4"}},{"id":1303125,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-14T16:32:37.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":27023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":219712,"source":{"system":"sec-edgar","filing":"0001104659-25-003462","document":"tm253183-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925003462/tm253183-3_4seq1.xml","form_type":"4"}},{"id":1307439,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-07T19:11:51.000Z","date":"2025-01-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":4416,"price":38.86,"value":171605.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":192689,"source":{"system":"sec-edgar","filing":"0001104659-25-001768","document":"tm252237-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925001768/tm252237-2_4seq1.xml","form_type":"4"}},{"id":1307438,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-07T19:11:51.000Z","date":"2025-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":5561,"price":38.19,"value":212374.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":197105,"source":{"system":"sec-edgar","filing":"0001104659-25-001768","document":"tm252237-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925001768/tm252237-2_4seq1.xml","form_type":"4"}},{"id":1307437,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-07T19:11:51.000Z","date":"2025-01-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":6934,"price":38.19,"value":264809.46,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":202666,"source":{"system":"sec-edgar","filing":"0001104659-25-001768","document":"tm252237-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465925001768/tm252237-2_4seq1.xml","form_type":"4"}},{"id":1341267,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-05T18:14:34.000Z","date":"2024-12-03","kind":"sale","planned":true,"acquired":false,"shares":8034,"price":42.2447,"value":339393.9198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.555. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":209600,"source":{"system":"sec-edgar","filing":"0001104659-24-125969","document":"tm2430055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924125969/tm2430055-2_4seq1.xml","form_type":"4"}},{"id":1341266,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-05T18:14:34.000Z","date":"2024-12-03","kind":"sale","planned":true,"acquired":false,"shares":11966,"price":41.7802,"value":499941.8732,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.09 to $42.085. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":217634,"source":{"system":"sec-edgar","filing":"0001104659-24-125969","document":"tm2430055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924125969/tm2430055-2_4seq1.xml","form_type":"4"}},{"id":1415096,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-04T16:05:15.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":3080,"price":42.075,"value":129591.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":229600,"source":{"system":"sec-edgar","filing":"0001104659-24-096869","document":"tm2423359-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924096869/tm2423359-1_4seq1.xml","form_type":"4"}},{"id":1415095,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-04T16:05:15.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4620,"price":41.1158,"value":189954.996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.77 to $41.725. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":232680,"source":{"system":"sec-edgar","filing":"0001104659-24-096869","document":"tm2423359-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924096869/tm2423359-1_4seq1.xml","form_type":"4"}},{"id":1415094,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-04T16:05:15.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":12300,"price":40.1145,"value":493408.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $40.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":237300,"source":{"system":"sec-edgar","filing":"0001104659-24-096869","document":"tm2423359-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924096869/tm2423359-1_4seq1.xml","form_type":"4"}},{"id":1482127,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T23:23:49.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":20594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the 2025 annual meeting of stockholders."}],"balance_after":20594,"derivative":{"exercise_price":17.13,"exercise_date":"2025-06-10","expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":20594},"source":{"system":"sec-edgar","filing":"0001562180-24-005018","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218024005018/primarydocument.xml","form_type":"4"}},{"id":1489365,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T16:07:38.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":385,"price":42.0366,"value":16184.091,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.99 to $42.065. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":249600,"source":{"system":"sec-edgar","filing":"0001104659-24-068673","document":"tm2416457-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924068673/tm2416457-1_4seq1.xml","form_type":"4"}},{"id":1489364,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T16:07:38.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":3651,"price":41.3767,"value":151066.3317,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.98 to $41.955. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":249985,"source":{"system":"sec-edgar","filing":"0001104659-24-068673","document":"tm2416457-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924068673/tm2416457-1_4seq1.xml","form_type":"4"}},{"id":1489363,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T16:07:38.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":4192,"price":40.6219,"value":170287.0048,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.98 to $40.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":253636,"source":{"system":"sec-edgar","filing":"0001104659-24-068673","document":"tm2416457-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924068673/tm2416457-1_4seq1.xml","form_type":"4"}},{"id":1489362,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T16:07:38.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":11772,"price":39.4015,"value":463834.458,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":257828,"source":{"system":"sec-edgar","filing":"0001104659-24-068673","document":"tm2416457-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924068673/tm2416457-1_4seq1.xml","form_type":"4"}},{"id":1683575,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-08T21:09:35.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":120000,"derivative":{"exercise_price":38.4,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001104659-24-002374","document":"tm242462-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924002374/tm242462-3_4seq1.xml","form_type":"4"}},{"id":1683574,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:09:35.000Z","date":"2024-01-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":5466,"price":41.53,"value":227002.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":269600,"source":{"system":"sec-edgar","filing":"0001104659-24-002374","document":"tm242462-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924002374/tm242462-3_4seq1.xml","form_type":"4"}},{"id":1683573,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:09:35.000Z","date":"2024-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":4469,"price":37.96,"value":169643.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":275066,"source":{"system":"sec-edgar","filing":"0001104659-24-002374","document":"tm242462-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924002374/tm242462-3_4seq1.xml","form_type":"4"}},{"id":1683572,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:09:35.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":42312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":279535,"source":{"system":"sec-edgar","filing":"0001104659-24-002374","document":"tm242462-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924002374/tm242462-3_4seq1.xml","form_type":"4"}},{"id":1855947,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T23:29:21.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":22123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders."}],"balance_after":22123,"derivative":{"exercise_price":9.55,"exercise_date":"2024-06-12","expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":22123},"source":{"system":"sec-edgar","filing":"0001562180-23-005175","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218023005175/primarydocument.xml","form_type":"4"}},{"id":2057209,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-10T16:05:03.000Z","date":"2023-01-07","kind":"tax_withholding","acquired":false,"shares":1483,"price":26.41,"value":39166.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":237223,"source":{"system":"sec-edgar","filing":"0001104659-23-002704","document":"tm232960-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465923002704/tm232960-5_4seq1.xml","form_type":"4"}},{"id":2058317,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option  (Right to Buy)","published_at":"2023-01-09T17:01:19.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person."}],"balance_after":135000,"derivative":{"exercise_price":27.64,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001104659-23-002321","document":"tm232787-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465923002321/tm232787-7_4seq1.xml","form_type":"4"}},{"id":2058316,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option  (Right to Buy)","published_at":"2023-01-09T17:01:19.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person."}],"balance_after":105000,"derivative":{"exercise_price":27.64,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-23-002321","document":"tm232787-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465923002321/tm232787-7_4seq1.xml","form_type":"4"}},{"id":2058315,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-09T17:01:19.000Z","date":"2023-01-06","kind":"tax_withholding","acquired":false,"shares":3326,"price":27.52,"value":91531.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4/A filed on January 14, 2022."}],"balance_after":238706,"source":{"system":"sec-edgar","filing":"0001104659-23-002321","document":"tm232787-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465923002321/tm232787-7_4seq1.xml","form_type":"4"}},{"id":2058314,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-09T17:01:19.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":33994,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."}],"balance_after":242032,"source":{"system":"sec-edgar","filing":"0001104659-23-002321","document":"tm232787-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465923002321/tm232787-7_4seq1.xml","form_type":"4"}},{"id":2220192,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T23:16:42.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":42087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 24, 2022 will become vested on the earlier of (i) June 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders."}],"balance_after":42087,"derivative":{"exercise_price":8.53,"exercise_date":"2023-06-08","expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":42087},"source":{"system":"sec-edgar","filing":"0001562180-22-005384","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218022005384/primarydocument.xml","form_type":"4"}},{"id":2434583,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-01-14T16:58:01.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":1852,"price":56.06,"value":103823.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":325813,"source":{"system":"sec-edgar","filing":"0001104659-22-004462","document":"tm223052-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465922004462/tm223052-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-01-11"}},{"id":2437331,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-01-11T16:02:15.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":2531,"price":56.06,"value":141887.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":325134,"source":{"system":"sec-edgar","filing":"0001104659-22-003142","document":"tm222586d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465922003142/tm222586d1_4.xml","form_type":"4"}},{"id":2438614,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option  (Right to Buy)","published_at":"2022-01-10T16:27:56.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":81420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person."}],"balance_after":81420,"derivative":{"exercise_price":59.46,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":81420},"source":{"system":"sec-edgar","filing":"0001104659-22-002752","document":"tm222382d8_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465922002752/tm222382d8_4.xml","form_type":"4"}},{"id":2438613,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-01-10T16:27:56.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":26124,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."}],"balance_after":327665,"source":{"system":"sec-edgar","filing":"0001104659-22-002752","document":"tm222382d8_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465922002752/tm222382d8_4.xml","form_type":"4"}},{"id":2647060,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-07-01T18:30:12.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":32000,"price":85.3465,"value":2731088.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $82.01 to $87.12, inclusive"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,038 restricted stock awards subject to time-based vesting."}],"balance_after":301541,"source":{"system":"sec-edgar","filing":"0001104659-21-088377","document":"tm2121303d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465921088377/tm2121303d1_4.xml","form_type":"4"}},{"id":2894659,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-26T16:31:12.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":32000,"price":84.0713,"value":2690281.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $81.76 to $89.00, inclusive"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 149,947 restricted stock awards subject to time-based vesting."}],"balance_after":261542,"source":{"system":"sec-edgar","filing":"0001104659-21-007671","document":"tm214262-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465921007671/tm214262-1_4seq1.xml","form_type":"4"}},{"id":2910417,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T09:28:36.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person."}],"balance_after":104000,"derivative":{"exercise_price":70.68,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001104659-21-002788","document":"tm2022926-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465921002788/tm2022926-7_4seq1.xml","form_type":"4"}},{"id":2910416,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-11T09:28:36.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards. The restricted stock awards shall vest as follows: thirty three percent (33%) to vest on January 7, 2022, another thirty three percent (33%) to vest on the second anniversary of January 7, 2023 and the remaining thirty four percent (34%) to vest on January 7, 2024, such that the restricted stock awards are fully vested on January 7, 2024."}],"balance_after":293542,"source":{"system":"sec-edgar","filing":"0001104659-21-002788","document":"tm2022926-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465921002788/tm2022926-7_4seq1.xml","form_type":"4"}},{"id":3226191,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T18:20:39.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person."}],"balance_after":100000,"derivative":{"exercise_price":33.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-20-029342","document":"tm2011556d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465920029342/tm2011556d1_4.xml","form_type":"4"}}]}